The approved corona vaccines could soon be joined by another one. A US vaccine is breaking new ground and, according to the manufacturer, has a number of advantages.
San Diego – Vaccines against the virus have proven to be an important tool in the fight against the corona pandemic. The vaccines from Moderna and Biontech/Pfizer work on the basis of mRNA. A third corona vaccine using this technology could soon be on the market.
The San Diego (US state of California) company Arcturus Therapeutics has apparently developed another mRNA-based corona vaccine. According to the pharmaceutical company, the vaccine called “ARCT-154” already has one efficacy study successfully accomplished.
Corona vaccine “ARCT-154” (Arcturus Therapeutics) multiplies in the body of the vaccinated person
According to this, Arcturus Therapeutics’ corona vaccine was 95 percent effective against serious illness or death during the phase 3 study. In addition, “ARCT-154” achieved a protective effect of 55 percent against symptoms in a person infected with the coronavirus. A total of 16,000 subjects took part in the vaccine study in Vietnam. During this period, the corona variants delta and omicron dominated.
However, one property of the new vaccine is unique to date. According to the manufacturer, the corona vaccine multiplies after administration in the body of the vaccinated person. On the one hand, “ARCT-154” works like the mRNA vaccines from Biontech/Pfizer and Moderna: It allows the body of the vaccinated person to produce a component of the coronavirus.
Corona vaccine “ARCT-154”: Lower dose should be sufficient, storage at room temperature
But the Arcturus Therapeutics vaccine also ensures that other proteins are produced in the body. These in turn stimulate cells to multiply the building instructions for the virus component. The aim is to decode and fight the coronavirus more effectively from the body’s own defenses through the human immune system.
Due to the multiplication mechanism of the corona vaccine “ARCT-154”, a low dose is sufficient for vaccination. In addition, according to Arcturus Therapeutics, less effort is required for storage than with competing products. The corona vaccine is delivered in powder form, which allows it to be stored at room temperature. Before administration, the vaccine must be mixed with a liquid. The corona vaccines from Biontech/Pfizer and Moderna, on the other hand, have to be stored in a cool place.
Corona vaccine “ARCT-154”: Manufacturer Arcturus Therapeutics has applied for emergency approval
According to Arcturus Therapeutics, this enables cheaper production. And a lower total amount is required than with previous mRNA-based corona vaccines. While the mRNA vaccines from Biontech/Pfizer needed 30 micrograms and Moderna 100 micrograms per corona vaccination, “ARCT-154” gets by with 5 micrograms per vaccination according to the study.
So the production site for “ARCT-154” is Vietnam. Arcturus Therapeutics has already applied for emergency approval for its corona vaccine in the Asian country. Another study to prove the booster effect of the vaccine is already being considered. Meanwhile, a new combination booster from Moderna has been able to convince in a study. (kh)
#corona #vaccine #ARCT154 #USA #beckons #approval #multiplies #body